DiaMedica Therapeutics (DMAC) Capital Expenditures (2018 - 2026)

DiaMedica Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $8000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 33.33% year-over-year to $8000.0 in Q1 2026; TTM through Mar 2026 was $36000.0, a 28.57% increase from a year earlier, with the FY2025 full-year figure at $40000.0, up 60.0% from the prior year.
• Capital Expenditures improved to $8000.0 in Q1 2026 per DMAC's latest filing, from $6000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $43000.0 in Q3 2022 and bottomed at $3000.0 in Q4 2023.
• The 5-year median for Capital Expenditures is $8000.0 (2026), against an average of $11866.7.
• Across the five-year window, Capital Expenditures surged 2050.0% in 2022 and sank 90.62% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $32000.0 in 2022, then sank by 90.62% to $3000.0 in 2023, then jumped by 133.33% to $7000.0 in 2024, then slipped by 14.29% to $6000.0 in 2025, then surged by 33.33% to $8000.0 in 2026.
• Per Business Quant, the three latest DMAC Capital Expenditures figures stand at $8000.0 (Q1 2026), $6000.0 (Q4 2025), and $16000.0 (Q3 2025).